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ABSTRACT
The newly developed Assessment of Burden of COPD (ABC) scale is a 14-item self-administered ques-
tionnaire which measures the physical, psychological, emotional and/or social burden as experienced by
patients with chronic obstructive pulmonary disease (COPD). The ABC scale is part of the ABC tool that
visualises the outcomes of the questionnaire. The aim of this study was to assess the reliability and con-
struct validity of the ABC scale. This multi-centre survey study was conducted in the practices of 19 general
practitioners and 9 pulmonologists throughout the Netherlands. Next to the ABC scale, patients with COPD
completed the Saint George Respiratory Questionnaire (SGRQ). Reliability analyses were performed with
data from 162 cases. Cronbach’s alpha was 0.91 for the total scale. Test-retest reliability, measured at a two
week interval (n = 137), had an intra-class correlation coefficient of 0.92. Analyses for convergent validity
were performed with data from 133 cases. Discriminant and known-groups validity was analysed with data
from 162 cases. The ABC scale total score had a strong correlation with the total score of the SGRQ (r= 0.72,
p< 0.001) but a weak correlationwith the forced expired volume in 1 second predicted (r= -0.28, p< 0.001).
Subgroupswithmore severe disease, defined by GOLD-stage, frequency of exacerbations, activity level and
depression scored statistically significantly (p< 0.05) worse on almost all domains of the ABC scale than the
less severe subgroups. The ABC scale seems a valid and reliable tool with good discriminative properties.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable lung disease, characterised by airflow
limitation that is not completely reversible (1, 2). COPD is a
major health concern worldwide and is projected to become
the number four most important cause of death, and the
7th-leading cause of disability-adjusted life years (DALY’s)
worldwide by 2030, worse than ranks 5 and 11 in 2002, respec-
tively (3).
The Dutch care guidelines for the management of COPD
have embraced the concept ‘burden of disease’ to stimulate a
holistic assessment of the burden of COPD as experienced by
the patient, followed by more personalized care management
(4). A Dutch national expert research team, commissioned by
the Dutch Lung Alliance, has defined burden of disease as the
physical, psychological, emotional and/or social burden as expe-
rienced by the patient (5), and this definition encompasses con-
siderably more than airway obstruction alone. To measure the
burden of COPD this definition needed to be operationalised
CONTACT Annerika H. M. Slok annerika.slok@maastrichtuniversity.nl Department of Family Medicine, Maastricht University, CAPHRI School for Public Health and
Primary Care, P.O. Box , , MDMaastricht, The Netherlands, fax:   
Color versions for one or more of the ﬁgures in the article can be found online at www.tandfonline.com/icop
into a measurement scale. A questionnaire was deemed to be
the most suitable method for this purpose.
The Dutch national expert research team also formulated a
number of conditions this questionnaire had to meet to opera-
tionalise the burden of disease concept (e.g., it should provide
insight in the (pathophysiologic) impairments, disabilities and
complaints due to COPD, it should be based on input by patients
and it should be easily manageable). A systematic review of the
literaturewas performed for existingCOPDquality of life/health
status questionnaires, but none of these encompassed all of the
aspects of the definition of the burden of COPD and fulfilled all
the conditions formulated by theDutch national expert research
team (5). However, the Clinical COPD Questionnaire (CCQ),
a 10-item self-administered questionnaire encompassed most
of these aspects and conditions, and was adapted into the new
Assessment of Burden of COPD (ABC) scale. This new ques-
tionnaire was created by combining the 10 items of the CCQ
with the 3 items of the Distress-screener (a short screening tool
for early identification of distress)(6), and by adding an item to
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measure fatigue (5). This resulted in a 14-item scale comprised
of 5 domains (Appendix A). Each item can be answered using a
Likert scale, ranging from 0 (asymptomatic/no limitation) to 6
(extremely symptomatic/ total limitation). The sub-score of each
of the domains and the total score can be calculated by adding
the value of the answers and dividing them by the number of
items. A low score on the ABC scale indicates a low experienced
burden of COPD.
TheABC scale is the core part of the Assessment of Burden of
COPD (ABC) tool. This tool visualises the questionnaire scores
and adds more objective indicators of the burden of COPD
(e. g., smoking status, lung function, exacerbation history) to
provide an overview of the individual patient’s integrated health
status. The questionnaire scores and objective indicators are
visualised using balloons. When a patient is doing well on a cer-
tain domain, the balloon is shown at the top end in green.When
a patient is not doing well, the balloon is shown at the bottom
end in red. The scores in between are visualised with orange bal-
loons in different shades. For example, when a patients scores
high on the emotion domain, the balloon is shown at the bot-
tom end in red (see Figure 1).
The tool has been developed to guide patients with COPD
and healthcare providers intomaking a personal treatment plan.
It facilitates in shared decision making between patients and
healthcare providers and formulating a personal goal. The tool
is also supposed to be used to monitor a patient’s experienced
burden of disease, since the scores of previous visit can also be
displayed (in grey balloons; see Figure 1, showing a grey balloon
at the symptoms domain). This provides the healthcare provider
and patient the possibility to discuss progression or deteriora-
tion.
Because the scores on the questionnaire determine the posi-
tion of the balloons, and because four questions were added to
the original CCQ, the reliability and validity of the new ABC
scale needed to be assessed. The researchers aimed to evaluate
the ABC scale by assessing the internal consistency of the total
ABC scale and its individual domains, the test-retest reliability
of the ABC scale and the construct validity of the ABC scale.
Methods
Study design
This research was part of a large two-armed randomised con-
trolled trial assessing the effectiveness of the Assessment of Bur-
den of Chronic Obstructive Pulmonary Disease (ABC) tool; the
study protocol of this cluster randomised trial has been pub-
lished elsewhere (7). The study was approved by the Medical
Ethics committee of Atrium-Orbis-Zuyd hospital, The Nether-
lands. This research is performedwith data collected in the prac-
tices of 19 general practitioners and 9 pulmonologists in the
Netherlands, whowere included in the intervention group of the
study.
Setting and subjects
The study population consisted of patients recruited by
primary and secondary care providers spread across the
Netherlands between 01-02-2013 and 01-10-2013. Inclusion cri-
teria were spirometrically confirmed diagnosis of COPD (post
bronchodilator forced expiratory volume in 1 second (FEV1) /
forced vital capacity (FVC) < 0.7), age > 40 years, and the abil-
ity to understand and read Dutch. Exclusion criteria were: exac-
erbation of COPD less than 6 weeks ago, hard drug addiction,
life-threatening co-morbid condition, and pregnancy.
All patients provided written informed consent prior to par-
ticipation in the study.
Data collection
Questionnaires
Next to the ABC scale, all patients completed the Saint George’s
Respiratory Questionnaire (SGRQ)(8), and the Hospital Anxi-
ety and Depression Scale (HADS)(9).
ABC scale
The ABC scale is a 14-item self-administered questionnaire
which has recently been developed to measure the burden of
COPD (5). It has a total score and 5 domain scores: symptoms (4
items), functional status (4 items), mental status (2 items), emo-
tions (3 items) and fatigue (1 item). All scores range from 0 to 6
(0 = no burden of disease, 6 = highest possible burden of dis-
ease).
The ABC scale was completed on paper in the waiting room
of the practices of the health care providers, at two occasions
with an interval of 2 weeks, without supervision. Treatment did
not change between these two measurements. With regard to
handling missing data, the original rules of the CCQ (10), of
which the ABC scale is largely composed, were followed and
similarly extended to the additional two domains. No missing
data was accepted for the mental status and fatigue domains; for
the other domains one missing value was tolerated. The score
for a single missing item from a subscale was inferred by using
the mean of the remaining items in the specific domain of that
patient. If the tolerated amount of missing data was exceeded,
the domain was judged as invalid, and total score could not be
calculated.
The total score of the ABC scale was calculated by adding
the sum scores of the five domains and dividing them by 5.
The domain scores were calculated by adding the items of the
domain and dividing them by the number of items of that
domain.
SGRQ
The SGRQ (8), a 50-item disease-specific health status question-
naire, consists of three different subscales: symptoms (8 items),
activity (16 items) and impact (26 items), and includes specific
item-weights which can be summated and divided by the max-
imum score to obtain a total score. Each of the sub-scores and
the total score range from0 to 100 (0= no impairment).Missing
data were handled as described in the SGRQ manual (11).
HADS
The HADS, a 14-item screening scale for anxiety and depres-
sion comprises two subscales: anxiety (7 items) and depression
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Figure . Visualization of the integrated health status, including the ﬁve domains of the ABC scale, and including a grey balloon.
(7 items). This questionnaire was originally developed for hos-
pital outpatient settings (9), but proved valid also for use in gen-
eral practice patients in theNetherlands (12, 13). All item-scores
range from 0 to 3 (0 = no signs of depression/anxiety). The
depression subscale-score is calculated as the sum of the depres-
sion item scores, and a cut-off score of 8 or higher was used
to discriminate between patients with depression or borderline
depression and patients with no depression (13). Missing data
was handled as described in the HADSmanual (14). The SGRQ
andHADSwere completed at home, on paper, or online (as cho-
sen by the patient).
Othermeasurements
Lung function parameters (FEV1 (in mL and as percentage
(%) of predicted) and FVC) were measured by the health care
providers using a spirometer according to the appropriate clin-
ical guidelines (1). Data concerning the number of COPD-
exacerbations in the past year were recorded by the health
care providers using the electronic registration program of this
study (7).
Data analysis
Reliability
Reliability can be divided into internal consistency and test-
retest reliability (15). To determine internal consistency, Cron-
bach’s alpha (16) was calculated for the total ABC scale and for
each of the five subscales. Since Cronbach’s alpha increases with
the number of items of a scale, α  0.90 for the 14-item ABC
scale was deemed acceptable, as compared to α  0.70 for each
of the subscales (17).
The 2-week test-retest reliability was expressed in terms of
the intraclass correlation coefficient (ICC). The first measure-
ment was 2 weeks before baseline (T0). No changes in ther-
apy were made between these two moments. A good reliability
(ICC  0.9) (18, 19) between both assessments (t = 0 and t =
−2 weeks) was hypothesized for the total score of the ABC scale.
Construct validity
Construct validity is defined as ‘the degree to which the scores
of an instrument are consistent with hypotheses based on the
assumption that the Health Related-questionnaire validly mea-
sures the construct to be measured (15). The assessment of con-
struct validity was subdivided into convergent validity, discrim-
inant validity and known-groups validity.
For the assessment of convergent validity, it was hypothe-
sized that theABC scale would show a strong correlationwith an
established COPD quality of life questionnaire. It would be ideal
to compare the ABC scale with a gold standard (20). However,
since no gold standard formeasuring burden of COPDcurrently
exists, the correlation between the total score of the ABC scale
and the total score of the SGRQ (8) was calculated, as is com-
mon practice when assessing validity of a COPD quality of life
questionnaire (21–23). As both theABC scale and the SGRQcan
be regarded health status instruments, it was hypothesized these
would show a strong correlation (r 0.70) (24) when evaluated
by Pearson’s correlation coefficient. Since both questionnaires
(SGRQ and ABC scale) were administered at different locations
at different time points, patients were only included in the anal-
yses if the questionnaires were completed within an interval of
one month.
For assessment of the discriminant validity, a weak correla-
tion was presumed with lung function (i.e., FEV1% predicted),
similar to findings of earlier studies (25–29). It was hypothesized
that Pearson’s correlation coefficient would be0.35 (24). In the
case of non-normally distributed data, Spearman’s rank correla-
tion coefficient was calculated and an equally weak correlation
was assumed.
To test known groups validity, four pairs of groups were cre-
ated based on (1) the number of exacerbations in the past year
( 2 vs < 2 per year), (2) the disease stage, as defined by the
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Table . Baseline characteristics of the study population (n= ).
Male sex, n (%)  (.)
Age, years, mean (SD) . (.)
Recruiting health care provider
General practitioners, n (%)  (.)
Pulmonologist, n (%)  (.)
Diagnosed COPD since, n (%)
< year  (.)
- year(s)  (.)
> years  (.)
Unknown  (.)
FEV/FVC ratio, mean (SD) . (.)
FEV, % predicted, mean (SD) . (.)
GOLD stage, n (%)
 (FEV >% predicted)  (.)
 (FEV -% predicted)  (.)
 (FEV -% predicted)  (.)
 (FEV <% predicted)  (.)
Number of exacerbations/year, n (%)
  (.)
  (.)
  (.)
>  (.)
ABC scale T, mean (SD)
Total score . (.)
Symptoms . (.)
Functional state . (.)
Mental state . (.)
Emotions . (.)
Fatigue . (.)
ABC scale T- wks, mean (SD)∗
Total score . (.)
Symptoms . (.)
Functional state . (.)
Mental state . (.)
Emotions . (.)
Fatigue . (.)
SGRQ total score, mean (SD) . (.)
SGRQ activity domain score . (.)
HADS total score, mean (SD) . (.)
HADS depression subscale . (.)
HADS anxiety subscale . (.)
aAbbreviations: SD: standard deviation, COPD: Chronic Obstructive Pulmonary Dis-
ease, FEV; ForcedExpiratory Volume in  second, FVC: ForcedVital Capacity, GOLD:
Global Initiative for Chronic Obstructive Lung Disease, ABC scale: Assessment of
BurdenofCOPD-scale, SGRQ: Saint-GeorgeRespiratoryQuestionnaire,HADS:Hos-
pital Anxiety and Depression Scale.
bT: baseline measurement of ABC scale together with all other questionnaires
(demographics, SGRQ, HADS); T-wks: measurement of ABC scale only,  weeks
prior to T.
c∗: n= .
Global Initiative for Chronic Obstructive LungDisease (GOLD)
in 2010 (1) (stage 3+4 vs stage 1+2, see Table 1), (3) level of
physical activity as assessed by activity subscale of the SGRQ (in-
active vs active (median as cut-off point)), and (4) depression
assessed by the depression subscale of the Hospital Anxiety and
Depression Scale (HADS) (depressed or borderline depressed vs
non-depressed) (9).
It was hypothesized that: patients with a history of frequent
exacerbations would show a statistically significant higher (i.e.,
worse) score on the symptoms domain of theABC scale, patients
with a higher GOLD classification would show a higher score on
the domains functional status and fatigue of the ABC scale, less
active patients would score higher on the domain functional sta-
tus and depressed or borderline depressed patients would show
a higher score on the mental state and emotional domains than
their respective counterparts. Differences between each group
in the known groups analysis were evaluated by performing
independent-sample t-tests. In case of non-normally distributed
data, theMann–Whitney U-test was used. A p-value< 0.05 was
considered statistically significant. The software used for statis-
tical analysis was IBM SPSS Statistics version 21.0.
Results
A total of 173 patients from 19 primary care practices and 9
pulmonology outpatient hospital practices contributed data for
the study. Since there were eleven cases missing in one or more
variables, analyses for the internal consistency were performed
on 162 complete cases. Characteristics of the study population
are presented in Table 1. The number of patients that completed
both measurements of the ABC scale was 137. Thus, the test-
retest reliability analysis was performed with these 137 cases.
Analyses for the convergent validity were performed with 133
complete cases who completed the ABC scale and the SGRQ
within an interval of one month. Discriminant validity and
known-groups validity were analysed with the complete 162
cases.
At baseline, patients’ total score on the ABC scale ranged
from 0.0 to 4.6. The scores of the subdomains ranged from 0.0
to 5.0 in the functional status domain, and 0.0 to 6.0 in the other
domains.
Reliability
Internal consistency
Cronbach’s alpha was 0.91 (95% Confidence Interval (CI):
0.88,0.93) for the 14-item ABC scale total score. Internal con-
sistencies of the domains symptoms (4 items), functional status
(4 items), mental status (2 items) and emotions (3 items) were
0.76 (95% CI: 0.68,0.81), 0.89 (95% CI: 0.87,0.92), 0.73 (95%
CI: 0.64,0.80), 0.87 (95% CI: 0.83,0.90) respectively. Because the
domain fatigue consisted of only one item, no internal consis-
tency could be calculated.
Test-retest reliability
The ICC was 0.92 (95% CI: 0.88,0.94) for the total score of the
two consecutive ABC scales taken two weeks apart.
Construct validity
Convergent and discriminant validity
The ABC scale total score and the total score of the SGRQ
showed a significant correlation of r = 0.72 (95% CI: 0.61,0.86;
p value < 0.001). The ABC scale score and the FEV1 (% pre-
dicted) showed a significant, but weak, correlation (r = −0.28
(95% CI: -0.43,-0.13; p value < 0.001). A table including corre-
lations between sub-scores of the domains is available for refer-
ence in Appendix B.
Known group validity
Results of the known groups analyses are presented in Table 2.
Patients with a history of frequent exacerbations showed a sig-
nificantly higher score on the symptoms domain of the ABC
scale. Patients with a higher GOLD classification had a signif-
icantly higher score on the domain functional state, but not on
the domain fatigue. In-active patients had a significantly higher
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Table . ABC scale subscale scores of known groups.
Known groups, median (interquartile range)
Exacerbations/year Gold stage Activity Depression
ABC  < + + Inactive† Active† (Borderline) Depressed‡ Non-depressed ‡
Subscales (n= ) (n= ) p (n= ) (n= ) p (n= ) (n= ) p (n= ) (n= ) p
Symptoms . (.–.) . (.–.) .∗∗ . (.–.) . (.–.) <.∗∗ . (.–.) . (.–.) .∗∗ . (.–.) . (.–.) .∗
Functional state . (.-.) . (.-.) <.∗∗ . (.-.) . (.-.) <.∗∗ . (.-.) . (.-.) <.∗∗ . (.-.) . (.-.) .∗∗
Mental state . (.-.) . (.-.) .∗∗ . (.-.) . (.-.) <.∗∗ . (.-.) . (.-.) <.∗∗ . (.-.) . (.-.) <.∗∗
Emotions . (.-.) . (.-.) .∗ . (.-.) . (.-.) . NS . (.-.) . (.-.) .∗∗ . (.-.) . (.-.) <.∗∗
Fatigue . (.-.) . (.-.) .∗∗ . (.-.) . (.-.) . NS . (.-.) . (.-.) <.∗∗ . (.-.) . (.-.) <.∗∗
aAbbreviations: ABC scale: Assessment of Burden of COPD scale, GOLD: Global Initiative for Chronic Obstructive Lung Disease, p: p-value.
bSigniﬁcance calculated by the Mann–Whitney-U test, depicted as: ∗∗P< . ∗P< . NS: non-signiﬁcant.
cABC scale: range  – :  indicating no burden of COPD and  indicating the worst burden of COPD.
d†: Patients were divided according to their score on the subscale Activity on the Saint George Respiratory Questionnaire (SGRQ), the median score (.) was used as
cut-oﬀ point.
e‡: As deﬁned by their scores on the Hospital Anxiety and Depression Scale (HADS) depression subscale. A cut-oﬀ score of was used to discriminate between patients
with depression or borderline depression and patients with no depression.
score on the domain functional state. Patients with depression
or borderline depression had a significantly higher score on both
the mental state and emotions sub-domains.
Discussion
This study shows a good internal consistency for the total ABC
scale and its’ individual domains. Furthermore, the test-retest
reliability showed an excellent correlation (ICC= 0.92) between
the measurements with a 2-week interval. As hypothesized, the
ABC scale correlated strongly with the SGRQ (r = 0.72) and
weakly with the FEV1 % predicted (r = -0.28)(27, 30). Even
though the different domains of the scale had good discrimi-
native properties (compared by median and mean scores), in
accordance with our hypothesis, this was not the case for the
fatigue domain when patients were grouped according to their
GOLD stage. Patients in GOLD stages 3 and 4 did not have a sig-
nificantly higher score on the fatigue domain than the patients
in GOLD stages 1 and 2. Additional analyses however showed
a significantly higher score of the fatigue domain in the inac-
tive patients, in the frequent exacerbators and also in depressed
and borderline depressed patients, consistent with other studies
(31–34) (see Table 2).
The ABC scale is the first questionnaire that attempts to fully
comply with the definition of burden of disease as the physical,
psychological, emotional and/or social burden as experienced
by the patient. It is an adaptation of the CCQ, with the addition
of the domains emotions and fatigue (5). The addition of the
two domains did not change the outcomes of the validity and
reliability analyses, as the reported values and correlation coef-
ficients for reliability and validity of the ABC scale were compa-
rable with the values reported in articles assessing the psycho-
metrics of the CCQ (21, 23).
The ABC scale is not developed to replace the CCQ in the
measurement of health status in daily clinical practice. The
ABC scale is developed to be an important part of the ABC
tool. This tool encompasses a visualization of the scores in
terms of a balloon-diagram and an algorithm that gives personal
treatment advice based on the integrated health status of the
patient, defined as the ABC scale score and the additional items;
smoking status, exacerbations, dyspnoea [as evaluated by the
MRC scale (35)], body mass index (BMI), lung function param-
eters, and physical activity. Use of the ABC tool facilitates more
personalized treatment of COPD. The ABC tool and its relation
to the ABC scale are described elsewhere (5).
Strengths and limitations
One could argue about the generalizability of the study popula-
tion. There were relatively few patients with GOLD stage 1 and
relatively many GOLD 3 patients as compared to the general
COPD population of the Netherlands (8.6% vs. 28% and 30.9%
vs. 15%, respectively) (36). The most obvious reason for this
imbalance is that almost half of the patients were recruited from
pulmonologists’ practices and therefore hadworse lung function
parameters, while the majority of the general COPD population
of the Netherlands are treated by their primary care physician.
This is unlikely to have influenced the results, since there was an
adequate number of patients from each of the GOLD stages 1–3,
and, as shown, FEV1 on which the GOLD stages are based does
not correlate well with burden of COPD.
A possible limitation of this study is the different locations at
which the questionnaires were filled out. Due to the design of the
study, the SGRQ and the HADS were filled out at home, while
the ABC scale was filled out in the waiting room of the health-
care providers practice (but without supervision), also result-
ing in a different time of administration. Since health status
changes over time, it would have been ideal to complete both
the SGRQ and the ABC scale at the same time point for assess-
ing their correlation. Due to this different time points of admin-
istration we only included patients in the analyses with a dif-
ference in administration-time of no longer than one month.
Analyses with the full sample (n= 162) yielded similar results as
the sub-sample analyses. The different locations could also have
resulted in a different completion behaviour. However, patients
came to the practices for their regular monitoring-appointment
and not specifically for the study. Furthermore, this applied for
all patients participating in the study.
Another possible limitation of this study is the lack of moni-
toring the patients’ clinical status, in the 2weeks between the two
measurements to perform the test-retest analysis. We therefore
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did not have information about whether patients were clinically
stable between those 2 weeks.
A major strength is the small number of missing data in
the SGRQ and HADS. There were 173 patients who filled
out questionnaires, and because only 11 cases missed one or
more baseline variables, analyses could be performed with 162
cases. This can partly be explained by the fact that approx-
imately one third of the patients completed the SGRQ and
the HADS in an online program, which ensured that patients
were unable to continue the questionnaire if questions were left
unanswered.
There was a larger amount of missing data for the first ABC-
scale that was specifically added to assess the 2-week test-retest
analysis (36 cases). This can partly be explained by the two visits
to the practice required to fill out both ABC-scales. Not every
patient filled out this first ABC-scale. Another 10 of the first
ABC scales were lost while beingmailed to the researcher. How-
ever, there is no reason to believe there is a systematic error due
to missing data in all of the analyses.
Another important strength of this study is its sample size
(n = 162); this is large as compared to the validity testing of the
CCQ (n = 119)(23), and especially compared to the test-retest
reliability (ABC scale n = 137, CCQ; n = 20). Furthermore,
the sample is highly representative for the Dutch COPD pop-
ulation, because the data originated from both primary and sec-
ondary care patients, distributed all over theNetherlands, which
decreases any possible regional influence.
Implications for clinical practice/research
This study shows that the ABC scale has good reliability and
validity. It can be deployed within the ABC tool to measure
the health status of the patient, to provide insight in the per-
sonal burden of COPD and to support the development of a
personalized treatment plan to decrease this burden. Together
with the ABC tool it can be used to facilitate the dialogue
about burden of COPD and to evaluate the effectiveness of the
interventions.
The responsiveness of the ABC scale needs to be determined
to see how the ABC scale score reflects change over time and the
effect of treatment interventions. This information is essential
for usability in daily practice. A study evaluating these charac-
terizations is currently ongoing. Additional research will be per-
formed to determine the importance of the items and domains
of the ABC scale from a patient’s perspective, by means of a Dis-
crete Choice Experiment.
Conclusion
The ABC scale is a 14-item self-administered questionnaire
that measures the burden of disease in patients with COPD.
Data presented in this study supports the reliability and con-
vergent and discriminant validity of the ABC scale for use in
patients with COPDboth in primary care and in secondary care.
Known groups analyses showed the ability of the ABC scale
to differentiate among different groups of patients. Additional
studies regarding the responsiveness and the minimally clinical
important difference, are needed before it can be implemented
in daily care as amethod towardsmore personalizedCOPDcare.
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Appendix A.
The Assessment Of Burden Of COPD (ABC) Scale
On average, during the past week, how often did you feel:
Hardly A few Several Many A great Almost all
Never ever times times times many times the time
 Short of breath at rest?       
 Short of breath doing physical activities?       
 Concerned about getting a cold or your breathing getting worse?       
 Depressed (down) because of your breathing problems?       
In general, during the past week, howmuch of the time:
Hardly A few Several Many A great Almost all
Never ever times times times many times the time
 Did you cough?       
 Did you produce phlegm?       
On average, during the past week, how limited were you in these activities because of your breathing problems:
Not limited Very slightly Slightly Moderately Very Extremely Totally limited/
at all limited limited limited limited limited or unable to do
 Strenuous physical activities (such as climbing stairs, hurrying,
doing sports)?
      
 Moderate physical activities (such as walking, house work, carrying
things)?
      
 Daily activities at home (such as dressing, washing yourself )?       
 Social activities (such as talking, being with children, visiting
friends/relatives)?
      
How often in the past week did you suffer from:
Hardly A few Several Many A great Almost all
Never ever times times times many times the time
 Worry?       
 Listlessness?       
 A tense feeling?       
 Fatigue?       
Appendix B.
Correlations betweenABC scale, the SGRQand FEV1%predicted
Assessment of Burden of COPD (ABC) scale
Symptoms p Functional state p Mental state p Emotions p Fatigue p Total p
Convergent validity (n= 133)
SGRQ
Symptoms . <. . <. . <. . <. . <. . <.
Activity . <. . <. . <. . . . <. . <.
Impact . <. . <. . <. . <. . <. . <.
Total . <. . <. . <. . <. . <. . <.
Discriminant validity (n= 162)
FEV % predicted − . <. − . <. − . <. − . . − . . − . <.
aAbbreviations: SGRQ: Saint-George Respiratory Questionnaire, FEV % predicted: Forced Expiratory Volume in  second, as a percentage of predicted for age group,
ABC scale: Assessment of Burden of COPD scale. b Due to non-normal distribution of data regarding the subscales of the ABC scale, Spearman’s rank correlation coeﬃcient
was calculated.
cABC scale: range  – :  indicating no burden of COPD and  indicating theworst burden of COPD. SGRQ: Saint George RespiratoryQuestionnaire, range (-) (higher
score indicates worse Health related Quality of Life).
